Attralus debuts with $25M series A to tackle systemic amyloidosis
Attralus looks to obtain clinical POC for first pan-amyloid therapy
Attralus debuted on Monday with a $25 million series A round from venBio Partners, a pan-amyloid imaging agent and a pair of candidates that can be developed for multiple types of systemic amyloidosis.
The company’s pan-amyloid molecules target motifs that are present on all amyloid fibrils and work by binding and removing fibrils from tissues throughout the body. The company’s initial focus will be on transthyretin amyloidosis (ATTR) and amyloid light chain (AL) amyloidosis...